H
Hana Müllerová
Researcher at AstraZeneca
Publications - 125
Citations - 7112
Hana Müllerová is an academic researcher from AstraZeneca. The author has contributed to research in topics: COPD & Exacerbation. The author has an hindex of 31, co-authored 101 publications receiving 5883 citations. Previous affiliations of Hana Müllerová include Kurume University & GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
John R. Hurst,Jørgen Vestbo,Jørgen Vestbo,Antonio Anzueto,Nicholas Locantore,Hana Müllerová,Ruth Tal-Singer,Bruce E. Miller,David A. Lomas,Alvar Agusti,William MacNee,Peter M.A. Calverley,Stephen I. Rennard,Emiel F.M. Wouters,Jadwiga A. Wedzicha +14 more
TL;DR: Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype, which has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity.
Journal ArticleDOI
C-reactive protein in patients with COPD, control smokers and non-smokers
Victor Pinto-Plata,Hana Müllerová,John Toso,Maurille Feudjo-Tepie,Joan B. Soriano,R. Vessey,Bartolome R. Celli +6 more
TL;DR: CRP levels are raised in COPD patients without clinically relevant IHD and independent of cigarette smoking, and reduced in patients with COPD using ICS, suggesting CRP may be a systemic marker of the inflammatory process that occurs in patientswith COPD.
Journal ArticleDOI
Inflammatory changes, recovery and recurrence at COPD exacerbation
W. R. Perera,John R. Hurst,Tom Wilkinson,Raymond J. Sapsford,Hana Müllerová,Gavin C. Donaldson,Jadwiga A. Wedzicha +6 more
TL;DR: Nonrecovery of symptoms at chronic obstructive pulmonary disease exacerbation is associated with persistently heightened systemic inflammation, and a high serum C-reactive protein concentration 14 days after an index exacerbation may be used as a predictor of recurrent exacerbations within 50 days.
Journal ArticleDOI
Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort.
Nicola A. Hanania,Hana Müllerová,Nicholas Locantore,Jørgen Vestbo,Jørgen Vestbo,Michael L. Watkins,Emiel F.M. Wouters,Stephen I. Rennard,Amir Sharafkhaneh,Amir Sharafkhaneh +9 more
TL;DR: Depression is more prevalent in subjects with COPD compared with smokers and nonsmokers without COPD and clinical and biologic measures were less important determinants of depression in COPD than disease symptoms and quality-of-life.
Journal ArticleDOI
Hospitalized Exacerbations of COPD: Risk Factors and Outcomes in the ECLIPSE Cohort
Hana Müllerová,Diego J. Maselli,Diego J. Maselli,Nicholas Locantore,Jørgen Vestbo,John R. Hurst,Jadwiga A. Wedzicha,Per Bakke,Per Bakke,Alvar Agusti,Antonio Anzueto,Antonio Anzueto +11 more
TL;DR: Exacerbations of COPD requiring hospital admission occur across all stages of airflow limitation and are a significant prognostic factor of reduced survival across all COPD stages.